Anti-Bacterial Agents - Adverse effects
Research News and Information

Saturday, November 21, 2009

A randomized trial of doxycycline for Mansonella perstans infection.

6 Oct 2009 BACKGROUND: Mansonella perstans infection is common in areas of Africa where Wuchereria bancrofti, a causative agent of lymphatic filariasis, is endemic. M. perstans is refractory to standard antifilarial therapies. The recent discovery of bacterial ... Read more...

The video head impulse test: diagnostic accuracy in peripheral vestibulopathy.

4 Oct 2009 BACKGROUND: The head impulse test (HIT) is a useful bedside test to identify peripheral vestibular deficits. However, such a deficit of the vestibulo-ocular reflex (VOR) may not be diagnosed because corrective saccades cannot always be detected by ... Read more...

Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis.

29 Sep 2009 Besifloxacin is a new fluoroquinolone anti-infective developed for ophthalmic use. Besifloxacin ophthalmic suspension 0.6% (Besivance) was recently approved for the treatment of bacterial conjunctivitis. The objective of this article is to provide a ... Read more...

Latest indexed articles for 'Anti-Bacterial Agents - Adverse effects'

These are the very latest articles for this heading:

• Minocycline-induced pigmentation of the aortic valve and sinuses of Valsalva. 30 Oct 2009
• Anaphylaxis and anesthesia: controversies and new insights. 30 Oct 2009
• A randomized trial of doxycycline for Mansonella perstans infection. 6 Oct 2009
• The video head impulse test: diagnostic accuracy in peripheral vestibulopathy. 4 Oct 2009
• Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis. 29 Sep 2009
• Aminoglycosides--engineering important patient-centered outcomes with antibiotics. 29 Sep 2009
• Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. 29 Sep 2009
• Variables influencing outcome of Helicobacter pylori eradication therapy in South China. 29 Sep 2009
• Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate. 29 Sep 2009
• Exposure-response analyses of tigecycline tolerability in healthy subjects. 29 Sep 2009
• Pursuing appropriateness of antimicrobial therapy prescription: is Italy on the move at last? 29 Sep 2009
• Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. 29 Sep 2009
• Infections in flares of inflammatory bowel disease. 29 Sep 2009
• Complications associated with postoperative antibiotic prophylaxis after breast surgery. 29 Sep 2009
• Mortality associated with cefepime therapy among neutropenic patients. 13 Sep 2009
• Mupirocin resistance. 13 Sep 2009
• Poultry, politics, and antibiotic resistance. 3 Sep 2009
• Does PPI therapy predispose to Clostridium difficile infection? 30 Aug 2009
• Drug interaction software and the risk of using ceftriaxone with therapeutic hemapheresis. 30 Aug 2009
• Linezolid: a review of safety and tolerability. 30 Aug 2009

See a longer list of these articles.

Technical information about 'Anti-Bacterial Agents'

Definition: Substances that reduce the growth or reproduction of BACTERIA.

Registry Number: 0

Descriptor UI: D000900

Alternative terms: Anti-Bacterial Agents; Agents, Anti-Bacterial; Anti Bacterial Agents; Antibacterial Agents; Agents, Antibacterial; Antibiotics; Bacteriocidal Agents; Agents, Bacteriocidal; Bacteriocides; Anti-Mycobacterial Agents; Agents, Anti-Mycobacterial; Anti Mycobacterial Agents; Antimycobacterial Agents; Agents, Antimycobacterial;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.954.122.085;

History Note: 2004(1963)

Technical Notes: GEN or unspecified; resistance to antibiotics = DRUG RESISTANCE, BACTERIAL or specifics; preop use of antibiotics for prev of infect: index under ANTIBIOTIC PROPHYLAXIS (IM) + specific antibiotic /ther use (IM)